TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31389718
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy
Study: 11096044
Drug: Combined conventional
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined conventional treatment and sorbent suspension dialysis (6-hour treatment)
Study: 9375591
Drug: Clomipramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine treatment starting at 10 mg/day, gradually increased to a mean dose of 97 mg/day
Study: 8262686
Drug: Pirenzepine and
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine and H2-receptor antagonists (cimetidine, ranitidine)
Study: 26417001
Drug: Adjuvant hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormone therapy (AHT) for 5 years
Study: 9278212
Drug: Theophylline (non-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (non-specific adenosine antagonist)
Study: 9278212
Drug: Dipyridamole (adenosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (adenosine reuptake inhibitor)
Study: 8020521
Drug: iomeprol 200
Normalized name: IOMEPROL
DrugBank: Iomeprol (DB11705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol 200 mgI/ml
Study: 8020521
Drug: iopamidol 200
Normalized name: iopamidol 200 mg iodine/mL (41 %) INJECTION VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopamidol 200 mgI/ml
Study: 2532444
Drug: Droperidol 0.010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.010 mg/kg
Study: 2532444
Drug: Droperidol 0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.005 mg/kg
Study: 810268
Drug: Intranasal betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal betamethasone valerate
Study: 31724354
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (conjugated estrogens and medroxyprogesterone acetate)
Study: 28323173
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy (CRT) + Optimal Pharmacological Therapy (OPT)
Study: 28323173
Drug: Optimal Pharmacological
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Pharmacological Therapy (OPT)
Study: 12594415
Drug: Combination headgear
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination headgear
Study: 12594415
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment until permanent dentition
Study: 10376260
Drug: 0.2 mg/cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/cc MMC
Study: 10376260
Drug: 0.4 mg/cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/cc MMC
Study: 3460737
Drug: Ofloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (300 mg) with breakfast
Study: 3460737
Drug: Ofloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (300 mg) fasting
Study: 27651908
Drug: Pulmonary artery
Normalized name: Pulmonary artery blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary artery perfusion with histidine‐tryptophan‐ketoglutarate (HTK) solution (n=29)
Study: 15933485
Drug: Fluoxetine/Paroxetine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine/Paroxetine (n = 298)
Study: 3108794
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of perioperative antibiotic prophylaxis with cefoperazone sodium
Study: 18245800
Drug: Various experimental
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various experimental treatments (specific treatments not detailed)
Study: 10100144
Drug: Vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m2 on days 1 and 8; Gemcitabine 1000 mg/m2 on days 1 and 8; Cisplatin 75 mg/m2 on day 8, repeated every 21 days for a maximum of six cycles.
Study: 10100144
Drug: Vinorelbine, gemcitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine, gemcitabine, and cisplatin combination therapy
Study: 8915032
Drug: Linomide (8-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linomide (8-9 mg/kg/day) in drinking water
Study: 8915032
Drug: Linomide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linomide (10 mg/kg) i.p. for 3 days
Study: 8915032
Drug: Linomide (8-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linomide (8-9 mg/kg/day) with rhIL-1beta (4.0 microg/kg) i.p. daily for 5 days
Study: 8915032
Drug: rhIL-1beta (4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIL-1beta (4.0 microg/kg) i.p. daily for 5 days
Study: 1745715
Drug: Lorazepam (0.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.0, 0.6, 0.13, 0.25, and 0.5 mg; total cumulative dose: 0.94 mg)
Study: 1745715
Drug: Lorazepam (0.94
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.94 mg)
Study: 30806017
Drug: Lidocaine 5%
Normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 5% patch
Study: 9506336
Drug: Cilostazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (200 mg/day)
Study: 8067708
Drug: ACNU or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACNU or BCNU (adjuvant chemotherapy)
Study: 30053572
Drug: Antidepressant consumption
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant consumption
Study: 23611212
Drug: Dasatinib 100
Normalized name: dasatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 100 mg orally daily
Study: 23611212
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg orally daily
Study: 20800376
Drug: Total body
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total body irradiation (TBI) with 800 cGy delivered in two 200‐cGy fractions twice a day before CD34(+) selected autologous hematopoietic stem cell transplantation.
Study: 17146008
Drug: C‐ECT (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐ECT (10 treatments)
Study: 14762617
Drug: Guidelines for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guidelines for epilepsy treatment based on the opinion of Brazilian experts
Study: 10750067
Drug: Daily iron/folate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron/folate supplementation
Study: 10750067
Drug: Once-weekly iron/folate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly iron/folate supplementation
Study: 31274545
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (ITM) with 100μg of morphine
Study: 20605441
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 10 mg
Study: 20605441
Drug: 1% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ropivacaine 20 mg
Study: 20605441
Drug: 0.5% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% levobupivacaine 10 mg
Study: 17921382
Drug: Iodine supplementation
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine supplementation (191 mg I as oral iodized oil)
Study: 17921382
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of iodine and vitamin A supplementation
Study: 8696714
Drug: MIP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIP regimen (mitomycin C 6 mg/m2 on day 1, ifosfamide 1500 mg/m2 on days 1-3, cisplatin 30 mg/m2 on days 1-3 every 4 weeks)
Study: 1948213
Drug: Cephalexin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (500 mg bid or qid)
Study: 1948213
Drug: Ofloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (300 or 400 mg bid)
Study: 30264137
Drug: Digital Cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Cognitive Behavioral Therapy (dCBT)
Study: 26545405
Drug: Doxorubicin/cyclophosphamide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin/cyclophosphamide treatment
Study: 17643586
Drug: High-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tirofiban + clopidogrel 600-mg loading dose
Study: 17643586
Drug: Eptifibatide +
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide + clopidogrel 600-mg loading dose
Study: 9809692
Drug: Alcohol restriction
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol restriction (maximum of 15 mL/day)
Study: 7631286
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist + beta-blocking agent
Study: 2575833
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg pindolol
Study: 2575833
Drug: 1.6 mg
Normalized name: menthol 1.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg pindolol
Study: 25633573
Drug: Paricalcitol 1
Normalized name: PARICALCITOL 1MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol 1 mcg administered orally once daily for three months
Study: 25633573
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally once daily for three months
Study: 22130240
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg intravenous bolus
Study: 22130240
Drug: 0.75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/kg intravenous bolus
Study: 22130240
Drug: 1.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.05 mg/kg intravenous bolus
Study: 22130240
Drug: 0.75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per hour infusion for 4 h
Study: 15253685
Drug: Intramuscular (i.m.)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (i.m.) IFNbeta-1a (Avonex)
Study: 15253685
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) IFNbeta-1a (Rebif)
Study: 11693798
Drug: Cisplatin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (30 mg/m2 daily for 3 days) + Vindesine (2.5 mg/m2 only day 1) + Dacarbazine (DTIC) (250 mg/m2 daily for 3 consecutive days) + Interferon-alpha (3 MIU i.m. 3x/wk continuously)
Study: 11693798
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) (800 mg/m2 day 1) + Interferon-alpha (3 MIU i.m. 3x/wk continuously)
Study: 8204227
Drug: 0.8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg/kg of i.v. ketorolac
Study: 8204227
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional analgesic (morphine only group)
Study: 3311438
Drug: One tablet
Normalized name: Hydone Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of Fansimef (250 mg mefloquine, 500 mg sulfadoxine, 25 mg pyrimethamine)
Study: 3311438
Drug: Two tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets of Fansimef
Study: 3311438
Drug: Three tablets
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three tablets of Fansimef
Study: 23811853
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (PIO) 15 mg/day
Study: 21457428
Drug: Canagliflozin (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (10, 30, 100, 200, 400, 600 or 800 mg q.d. or 400 mg b.i.d.)
Study: 21457428
Drug: Canagliflozin (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (doses >200 mg before breakfast)
Study: 17057562
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 40 mg + Ketorolac 60 mg
Study: 17057562
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 40 mg
Study: 8707552
Drug: Ketorolac 60
Normalized name: ketorolac 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 60 mg
Study: 17057562
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C): IM chorpheniramine 20 mg + IV normal saline
Study: 15064540
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by interval debulking surgery
Study: 9400786
Drug: MSL-109, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSL-109, 60 mg intravenously every 2 weeks
Study: 9400786
Drug: MSL-109, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSL-109, 60 mg intravenously every 2 weeks (relapsed retinitis)
Study: 9400786
Drug: MSL-109, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSL-109, 60 mg intravenously every 2 weeks (newly diagnosed retinitis)
Study: 8265305
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of human serum immunoglobulin (300 mg/kg body weight)
Study: 28255655
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL of 1% HA (H-HA)
Study: 28255655
Drug: 0.8 mL
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mL of 1% HA (L-HA)
Study: 28255655
Drug: 2.5 mL
Normalized name: syringe, disposable, 2.5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL of 0.01% HA (control group)
Study: 25171889
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy for primary care (PST-PC)
Study: 19083441
Drug: Antioxidant vitamins
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamins (vitamin C 1000 mg and vitamin E 800 IU)
Study: 8061849
Drug: Spirapril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril treatment (initial dose 6 or 12 mg once daily, titrated to 3-24 mg)
Study: 8061849
Drug: Spirapril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril treatment
Study: 4904222
Drug: Hyperosmolar and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperosmolar and hypoosmolar solutions
Study: 11099758
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of dexamphetamine sulphate
Study: 11099758
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of dexamphetamine sulphate
Study: 7921303
Drug: Daily vitamin
Normalized name: Daily Vitamin Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin and mineral supplements for 6 years
Study: 7921303
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation of four different vitamin and mineral combinations for 5 1/4 years
Study: 24256453
Drug: Group music
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group music therapy (GMT)
Study: 29798206
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with 10mg oral ebastine plus 200 μg intranasal mometasone furoate once daily (combined group)
Study: 29798206
Drug: Double-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose oral ebastine 20 mg once daily (double-dose group)
Study: 22561772
Drug: Muscle Relaxant
Normalized name: MUSCLE RELAXANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle Relaxant + anti‐depressant drug (n=26)
Study: 22561772
Drug: Physiotherapy +
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiotherapy + antidepressant drug + muscle relaxant (n=6)
Study: 19667999
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metformin 1700 mg/day and rosiglitazone 4 mg/day
Study: 15136950
Drug: Metformin 1700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1700 mg/day
Study: 18721168
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin infusion (CSII), n = 34
Study: 18721168
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections (MDI), n = 38
Study: 17135985
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluoxetine (FLX) and cognitive-behavioral therapy (CBT)
Study: 17135985
Drug: Clinical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical management with pill placebo (PBO)
Study: 14575277
Drug: manidipine 20
Normalized name: manidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: manidipine 20 mg daily
Study: 14575277
Drug: nifedipine 60
Normalized name: nifedipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 60 mg daily
Study: 1383574
Drug: finasteride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: finasteride (10 mg per day)
Study: 3996091
Drug: Tinidazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (500 mg intravenous infusion)
Study: 2888606
Drug: Oral tinidazole
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tinidazole
Study: 31291515
Drug: Galcanezumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab (300 mg, subcutaneously at baseline and at 1 month)
Study: 31291515
Drug: Galcanezumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab (300 mg)
Study: 24853120
Drug: Curcuminoids (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids (1500 mg/day in 3 divided doses)
Study: 12053718
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose therapy
Study: 27093747
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (15 g)
Study: 7607713
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg losartan + 25 mg hydrochlorothiazide
Study: 7607713
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg losartan + 25 mg hydrochlorothiazide
Study: 7607713
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg losartan + 25 mg hydrochlorothiazide
Study: 7607713
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + 25 mg hydrochlorothiazide
Study: 2218421
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg once daily for 10-14 days
Study: 2218421
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg once daily followed by 100 mg once daily for 10-14 days
Study: 28455250
Drug: Video and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video and oral sucrose solution (sucrose)
Study: 28455250
Drug: Video and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video and sucrose and topical liposomal lidocaine (lidocaine)
Study: 26266386
Drug: Sufentanil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil plus dexmedetomidine (0.02 μg/kg/h sufentanil + 0.05 μg/kg/h dexmedetomidine) (Group D2)
Study: 26266386
Drug: Sufentanil (0.02 μg/kg/h)
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil (0.02 μg/kg/h) (Group C)
Study: 26266386
Drug: Sufentanil plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil plus dexmedetomidine (0.02 μg/kg/h sufentanil + 0.02 μg/kg/h dexmedetomidine) (Group D1)
Study: 24057042
Drug: Lapatinib (1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1,250 mg once daily) and Everolimus (5 mg once daily)
Study: 24057042
Drug: Lapatinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib and Everolimus combination
Study: 12716684
Drug: 4.5 g
Normalized name: Zosyn 4.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g ALA/d
Study: 12663273
Drug: 9.5 g
Normalized name: Pedia-Lax Saline, 9.5 g-3.5 g/66 mL rectal enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.5 g ALA/d
Study: 12716684
Drug: 0.77 g
Normalized name: ISOPROPYL ALCOHOL 0.77 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.77 g EPA+DHA/d
Study: 12663273
Drug: 1.7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 g EPA+DHA/d
Study: 1345038
Drug: Pyruvate (36-53
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyruvate (36-53 g)
Study: 1345038
Drug: Placebo (Polycose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Polycose, 21-37 g)
Study: 21681921
Drug: IL-2 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 therapy infused on days 0-3 and 8-17
Study: 21681921
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy (AML control group)
Study: 11294480
Drug: Brofaromine (reversible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine (reversible monoamine oxidase A inhibitor)
Study: 9398716
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg, three times daily for 4-6 weeks)
Study: 7049817
Drug: Atenolol, 100
Normalized name: Atenolol, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, 100 mg once daily
Study: 24684734
Drug: Transdermal clonidine
Normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal clonidine (5 mg patch)
Study: 23557068
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg udenafil + tamsulosin placebo
Study: 23557068
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg udenafil + 0.4 mg tamsulosin
Study: 23557068
Drug: udenafil placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: udenafil placebo + 0.4 mg tamsulosin